Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening.
Menzin
A W
AW
Department of Obstetrics and Gynecology, North Shore University Hospital, North Shore-Long Island Jewish Health System, Manhasset, New York, USA.
Gal
D
D
Barakat
R R
RR
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D020847:Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008403:Mass Screening; D011159:Population Surveillance; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen